Podrobný výpis o publikaci

SVOBODA, Marek, Jitka BERKOVCOVÁ, Pavel FABIAN, Ingrid VÁŠOVÁ a Dana DVOŘÁKOVÁ. VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION. Annals of Oncology. European Society for Medical Oncology, 2005, roč. 2005, Suppl5, s. 173. ISSN 0923-7534.

Další formáty: BibTeX LaTeX RIS

TY  - JOUR
ID  - 726205
AU  - Svoboda, Marek - Berkovcová, Jitka - Fabian, Pavel - Vášová, Ingrid - Dvořáková, Dana
PY  - 2005
TI  - VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION
JF  - Annals of Oncology
VL  - 2005
IS  - Suppl5
SP  - 173
EP  - 173
PB  - European Society for Medical Oncology
SN  - 09237534
KW  - Lymphoma
KW  - protein kinase C
KW  - prediction
N2  - Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkins lymphoma, characterized by its clinical heterogenity. Global gene expression profiling subdivide the DLBCL into two main clinically and biologically distinct subgroups. Gene expression signatures characteristic of particular subgroups include different isophorms of protein kinase C (PKCs). According microarrays analyses, the increased expression of PKC-delta (PKCD) and PKC-gamma (PKCG) is present in DLBCL with favourable prognosis, but PKC beta I (PKCBI) and II (PKCBII) is present in fatal or refractory DLBCL. Methods: We used Reverse-Transcription PCR (RT-PCR), Quantitative Real-Time PCR (QRT-PCR) and immunohistochemical (IHC) analyses to validate the expression of selected PKCs isophorms in formalin fixed and paraffin embed (FFPE) tumor specimens from 52 patients treated for DLBCL between 1996 and 2003. Results: 1) We developed modified technique for RNA isolation from FFPE tumor specimens producing RNA of sufficient quantity and suitable quality for RT-PCR and QRT-PCR. 2) Using the IHC, RT-PCR, QRTPCR and DNA sequenation we confirmed that B-lymphocytes do not express PKCG. 3) We found that DLBCL patients, who achieved complete or partial remission after the first course of chemotherapy, and patients remained alive at 20-month follow-up, express low level of PKCD mRNA (P = 0.0089 and P = 0.0064 respectively). Conclusions: Data from microarray analyses need to be interpreted cautiously. PKCD seems to be potential predictive and prognostic marker in DLBCL.
ER  -

Základní údaje
Originální název	VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION
Název česky	Validace vybraných izoforem proteinkinasy C pro predikci vývoje difúzního velkobuněčného B-lymfomu.
Autoři	SVOBODA, Marek (203 Česká republika, garant), Jitka BERKOVCOVÁ (203 Česká republika), Pavel FABIAN (203 Česká republika), Ingrid VÁŠOVÁ (203 Česká republika) a Dana DVOŘÁKOVÁ (203 Česká republika).
Vydání	Annals of Oncology, European Society for Medical Oncology, 2005, 0923-7534.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30200 3.2 Clinical medicine
Stát vydavatele	Velká Británie a Severní Irsko
Utajení	není předmětem státního či obchodního tajemství
Impakt faktor	Impact factor: 4.319
Organizační jednotka	Lékařská fakulta
UT WoS	000233670100465
Klíčová slova anglicky	Lymphoma; protein kinase C; prediction
Štítky	Lymphoma, Prediction, protein kinase C
Příznaky	Mezinárodní význam, Recenzováno
Změnil	Změnil: prof. MUDr. Marek Svoboda, Ph.D., učo 19402. Změněno: 14. 10. 2007 00:11.

Anotace
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkins lymphoma, characterized by its clinical heterogenity. Global gene expression profiling subdivide the DLBCL into two main clinically and biologically distinct subgroups. Gene expression signatures characteristic of particular subgroups include different isophorms of protein kinase C (PKCs). According microarrays analyses, the increased expression of PKC-delta (PKCD) and PKC-gamma (PKCG) is present in DLBCL with favourable prognosis, but PKC beta I (PKCBI) and II (PKCBII) is present in fatal or refractory DLBCL. Methods: We used Reverse-Transcription PCR (RT-PCR), Quantitative Real-Time PCR (QRT-PCR) and immunohistochemical (IHC) analyses to validate the expression of selected PKCs isophorms in formalin fixed and paraffin embed (FFPE) tumor specimens from 52 patients treated for DLBCL between 1996 and 2003. Results: 1) We developed modified technique for RNA isolation from FFPE tumor specimens producing RNA of sufficient quantity and suitable quality for RT-PCR and QRT-PCR. 2) Using the IHC, RT-PCR, QRTPCR and DNA sequenation we confirmed that B-lymphocytes do not express PKCG. 3) We found that DLBCL patients, who achieved complete or partial remission after the first course of chemotherapy, and patients remained alive at 20-month follow-up, express low level of PKCD mRNA (P = 0.0089 and P = 0.0064 respectively). Conclusions: Data from microarray analyses need to be interpreted cautiously. PKCD seems to be potential predictive and prognostic marker in DLBCL.

Anotace

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkins lymphoma, characterized by its clinical heterogenity. Global gene expression profiling subdivide the DLBCL into two main clinically and biologically distinct subgroups. Gene expression signatures characteristic of particular subgroups include different isophorms of protein kinase C (PKCs). According microarrays analyses, the increased expression of PKC-delta (PKCD) and PKC-gamma (PKCG) is present in DLBCL with favourable prognosis, but PKC beta I (PKCBI) and II (PKCBII) is present in fatal or refractory DLBCL. Methods: We used Reverse-Transcription PCR (RT-PCR), Quantitative Real-Time PCR (QRT-PCR) and immunohistochemical (IHC) analyses to validate the expression of selected PKCs isophorms in formalin fixed and paraffin embed (FFPE) tumor specimens from 52 patients treated for DLBCL between 1996 and 2003. Results: 1) We developed modified technique for RNA isolation from FFPE tumor specimens producing RNA of sufficient quantity and suitable quality for RT-PCR and QRT-PCR. 2) Using the IHC, RT-PCR, QRTPCR and DNA sequenation we confirmed that B-lymphocytes do not express PKCG. 3) We found that DLBCL patients, who achieved complete or partial remission after the first course of chemotherapy, and patients remained alive at 20-month follow-up, express low level of PKCD mRNA (P = 0.0089 and P = 0.0064 respectively). Conclusions: Data from microarray analyses need to be interpreted cautiously. PKCD seems to be potential predictive and prognostic marker in DLBCL.

Anotace česky
Publikace pouze v anglickém jazyce